Synthesis and activity of a new class of dual acting norepinephrine and serotonin reuptake inhibitors: 3-(1H-indol-1-yl)-3-arylpropan-1-amines

  • Mahaney P
  • Vu A
  • McComas C
 et al. 
  • 1

    Readers

    Mendeley users who have this article in their library.
  • N/A

    Citations

    Citations of this article.

Abstract

Compounds with a combination of norepinephrine and serotonin reuptake inhibition have been approved in the US and Europe for a number of indications, including major depressive disorder and pain disorders such as diabetic neuropathy and fibromyalgia. Efforts to design selective norepinephrine reuptake inhibitors based on SAR from the aryloxypropanamine series of monoamine reuptake inhibitors have led to the identification of a potent new class of dual acting norepinephrine and serotonin reuptake inhibitors, namely the 3-(1H-indol-1-yl)-3-arylpropan-1-amines.

Author-supplied keywords

  • Adrenergic Uptake Inhibitors/chemical synthesis/ph
  • Tumor/drug effects; Choriocarcinoma/drug therapy/

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document

Authors

  • P E Mahaney

  • A T Vu

  • C C McComas

  • P Zhang

  • L M Nogle

  • W L Watts

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free